Caribou Biosciences Stock
Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular.
About Caribou Biosciences Stock
Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins.
Funding History
| October 2014 | $2.9M |
|---|---|
| March 2015 | $11.5M |
| May 2016 | $30.0M |
Management
Co-Founder
Jennifer A. Doudna
Co-founder
James Berger
Group Leader, Agriculture and Industrial Biotechnology
Vonnie Estes
Chief Legal Officer, Corporate Secretary
Barbara McClung
Co-Founder , President & CEO
Rachel E. Haurwitz
Vice President of Informatics
Chris Fuller
Co-founder
Martin Jinek
Chief Scientific Officer
Andy May
Vice President of Platform Re
Scott Gradia
Press
TechCrunch - Sep, 4 2018
Business Wire (press release) - May, 3 2018
OZY - Mar, 16 2018
Business Wire (press release) - Jul, 6 2017
- Dec, 16 2016
- Dec, 7 2016
- Oct, 27 2016
- Sep, 27 2016
- Sep, 23 2016
- Sep, 22 2016
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Caribou Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
